Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT

•BSH leads to high 10B concentration ratios between sarcoma, muscle and brain as well as between glioblastoma and brain.•The 10B concentration in tumors is quite low as is the 10B concentration ratio between tumors and blood.•BPA-f leads to 10B accumulation in tumors relative to blood and advantageous absolute 10B concentrations in tumors.•The 10B concentration ratios between tumors and brain and sarcoma and muscle, are modest.•The advantage of the sequential injection of both compounds is an enhanced intratumoral 10B concentration.

10B-concentration ratios between human glioblastoma multiforme (U87MG), sarcoma (S3) and melanoma (MV3) xenografted in nu/nu mice and selected normal tissues were investigated to test for preferential 10B-accumulation. Animals received BSH, BPA or both compounds sequentially. Mean 10B-concentration ratios between tumor and normal tissues above 2 were found indicating therapeutic ratios. In addition to glioblastoma, brain metastases and soft tissue sarcoma appear to be promising targets for future BNCT research.